obstructive sleep apnea, FDA and obesity

FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
This Weight Loss Drug Could Also Treat Sleep Apnea
If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a good fit.
FDA approves Zepbound for obstructive sleep apnea
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.
The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.
GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea
“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Dr. Sally Seymour, director of the Division of Pulmonology, Allergy, and Critical Care in the FDA’s Center for Drug Evaluation and Research, said in a news release. “This is a major step forward for patients with obstructive sleep apnea.”
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025
In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...
emjreviews.com3d
Eli Lilly’s tirzepatide wins FDA nod for sleep apnea
Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...